Philip Breitfeld's most recent trade in Champions Oncology Inc was a trade of 4,150 Common Stock done . Disclosure was reported to the exchange on March 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Champions Oncology Inc | Philip Breitfeld | Director | Other type of transaction at price $ 0.00 per share. | 25 Mar 2025 | 4,150 | 5,717 (0%) | 0% | 0 | Common Stock | |
| Champions Oncology Inc | Philip Breitfeld | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2024 | 18,715 | 18,715 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | Philip Breitfeld | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Nov 2023 | 15,495 | 15,495 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | Philip Breitfeld | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 11,480 | 11,480 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | Philip Breitfeld | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Oct 2022 | 8,333 | 0 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | Philip Breitfeld | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.21 per share. | 12 Oct 2022 | 8,333 | 18,200 (0%) | 0% | 3.2 | 26,749 | Common Stock |
| Champions Oncology Inc | Philip Breitfeld | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.51 per share. | 12 Oct 2022 | 3,562 | 14,638 (0%) | 0% | 7.5 | 26,751 | Common Stock |
| Champions Oncology Inc | Philip Breitfeld | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.65 per share. | 23 Mar 2021 | 4,167 | 4,167 (0%) | 0% | 3.7 | 15,210 | Common Stock |
| Champions Oncology Inc | Philip Breitfeld | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2021 | 4,167 | 0 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | Philip Breitfeld | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.35 per share. | 23 Mar 2021 | 1,340 | 2,827 (0%) | 0% | 11.4 | 15,209 | Common Stock |
| Champions Oncology Inc | Philip Breitfeld | Director | Sale of securities on an exchange or to another person at price $ 11.35 per share. | 16 Dec 2020 | 31,443 | 0 (0%) | 0% | 11.4 | 356,976 | Common Stock |
| Champions Oncology Inc | Philip Breitfeld | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2020 | 8,333 | 8,333 | - | - | Option to purchase Common Stock |